Avid Bioservices Inc (CDMO)

[irishpark]

it appears there had been a trial for ramucirumab along with docetaxel for HER2-negative, advanced breast cancer which did not produce the expected halt in disease progression.

After a median follow-up of 16.2 months, progression-free survival was 9.5 months in the ramucirumab arm and 8.2 months in the control arm.

Wonder if a combo trial with Bavi thrown in would be beneficial to a study like this.

http://www.news-medical.net/news/20131216/Combination-of-ramucirumab-and-docetaxel-fails-to-delay-advanced-breast-cancer-progression.aspx